Abdominal Aortic AneurysmNCT06775821
Epidemiology of Abdominal Aortic Aneurysm With Concomitant Primary Lung Cancer
An observational study of Abdominal Aortic Aneurysm and Primary Lung Cancer, run by First Affiliated Hospital of Kunming Medical University at 2 sites in China.
Trial summary
Retrospective clinical case studies in recent years have shown that most cases of lung cancer and abdominal aortic aneurysm (AAA) are detected at the same time and that there is a wide variation in the prevalence of AAA in patients with primary lung cancer reported in the literature, with some papers suggesting as… Read more about this study
- Who is it for?
- Ages 20 to 90 years
- Conditions the study is for
- Abdominal Aortic Aneurysm, Primary Lung Cancer, Prevalence
- What is being tested?
- Ultrasound or CT of the abdominal aorta
- Type of treatment
- Medical device
- How many people
- 2,000 participants
- Where
- 2 sitesChina
- Study dates
- 1 Oct 2022to 30 Apr 2025
- How long will I take part?
- 1 Year
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 90 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The selected subjects for the study were all patients diagnosed with primary lung cancer at the First Affiliated Hospital of Kunming Medical University and the Third Affiliated Hospital of Kunming Medical University from 1st October 2022 to 30 st April 2025, with an estimated sample size of about 2000 people. Detailed epidemiological data and long-term follow-up data were collected and analyzed, and epidemiological investigations were conducted.
Who may be able to join
- Patients diagnosed with primary lung cancer through clinical or pathological examination
Who cannot join
- Patients diagnosed with primary lung cancer who refuse to undergo abdominal aortic imaging screening.
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
China2 sites, 2 recruiting
- Recruiting
The First Affiliated Hospital of Kunming Medical University
Kunming, Yunnan, 650000
Yun-fei shi, Mphil, 13908716639
- Recruiting
The Third Affiliated Hospital of Kunming Medical University
Kunming, Yunnan, 650000
Xu-dong Xiang, MPhil, 13108519813
About this study
Retrospective clinical case studies in recent years have shown that most cases of lung cancer and abdominal aortic aneurysm (AAA) are detected at the same time and that there is a wide variation in the prevalence of AAA in patients with primary lung cancer reported in the literature, with some papers suggesting as high as 11%, suggesting that there may be a relationship between the prevalence of the two diseases. However, its exact incidence and mechanism are unknown. Accurate prevention of AAA in patients with primary lung cancer requires more in-depth studies. To solve the above problems, a multi-center prospective epidemiological investigation and mechanism study on the association of AAA in primary lung cancer combined has become particularly urgent. The results of the study will be of great significance for the follow-up treatment and prognosis of lung cancer patients as well as the improvement of long-term survival rate of lung cancer patients, and will also provide scientific basis and clinical guidance for the screening and prevention of AAA in lung cancer patients.
Read the detailed description
- research purpose： This study collected detailed basic information, lifestyle habits, past medical history, and laboratory indicators from 2000-3000 outpatient patients with primary lung cancer for data analysis and long-term follow-up. The study analyzed the related factors of lung cancer complicated with AAA, providing direct scientific evidence to better guide lung cancer patients in screening for AAA, identifying common high-risk factors for lung cancer patients complicated with AAA, providing clinical guidance for the prevention of AAA, and reducing the risk of AAA rupture. The research results are of great significance for the subsequent treatment and prognosis of lung cancer patients, as well as improving the long-term survival rate of lung cancer patients. They will also provide scientific basis and clinical guidance for the screening and prevention of AAA in lung cancer patients. Early detection and treatment of AAA can reduce the risk of AAA rupture, greatly improve the prognosis of lung cancer patients with AAA, and enhance their quality of life.
- research population： The research subjects are patients diagnosed with primary lung cancer at the Third Affiliated Hospital of Kunming Medical University and the First Affiliated Hospital of Kunming Medical University from 1st October 2022 to 30 st April 2025. The expected sample size is about 2000 people, and the age of patients is 20-90 years old. Collect detailed epidemiological data and long-term follow-up data, conduct statistical analysis, and conduct epidemiological investigations.
- Epidemiological data collection:
3.1 Basic Information: name, gender, ethnicity, age, height, weight, hometown, occupation, education level, ID card, phone number, and medical record number.
3.2 Behavioral Life Information：Whether smoking, smoking index, alcohol consumption, alcohol content and quantity consumed, history of exposure to asbestos products, dietary habits, and history of dust exposure.
3.3 Past medical history and family genetic history: Presence of hypertension, degree of hypertension, blood pressure control medications, and blood pressure control; diabetes mellitus, blood glucose control medications, and blood glucose control; hyperlipidemia, elevated lipid composition, lipid control medications, and lipid control; urologic disorders; family history of vascular disorders; and family history of oncologic disorders.
3.4 Laboratory information: Blood pressure, fasting blood glucose, glycosylated hemoglobin Total cholesterol (TC), triglyceride (TG), high-density lipoprotein-cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C).
3.5 Follow-up information:
- Information related to primary lung cancer: types of lung tumors (squamous cell carcinoma, adenocarcinoma, small cell/neuroendocrine/other); Staging of lung tumors (stages I, II, III, IV); CNM staging; Differentiation results of lung tumors; Immunohistochemical staining results; Tumor markers (outliers); Tumor genes (outliers); The treatment methods for lung tumors (surgery, radiotherapy, chemotherapy, molecular targeting, immunity, biological therapy, neoadjuvant chemotherapy); Surgical time and bleeding volume.
- Information related to abdominal aortic aneurysm: whether it is complicated with abdominal aortic aneurysm; Is there a concomitant iliac artery aneurysm; Whether to undergo surgical treatment; Surgical treatment methods (endovascular repair of abdominal aortic aneurysm, open surgery); Surgical time and bleeding volume.
- Patient prognosis: last follow-up time, time of lung tumor recurrence, whether death occurred, and cause of death.
4.Data entry and analysis At the Department of Thoracic Surgery of the First Affiliated Hospital of Kunming Medical University and the Department of Thoracic Surgery of the Third Affiliated Hospital of Kunming Medical University, patient basic information, laboratory tests, and treatment plans are obtained and filled out from the hospital's medical record system. Epidemiological survey questions are collected at the patient's bedside using a question and answer format to ensure the accuracy and reliability of the epidemiological survey information. All collected data is organized and encoded using REDCap（ https://www.wcrcnet.cn/redcap/ ）Perform data entry. IBM SPSS Statistics 22 will be used to analyze the entered data and identify the risk factors for primary lung cancer combined with AAA.
- Conditions
- Abdominal Aortic Aneurysm, Primary Lung Cancer, Prevalence
- Being tested
- Ultrasound or CT of the abdominal aorta
- Keywords
- Abdominal Aortic Aneurysm, primary lung cancer, epidemiological studies, prevalence
- Medical subject headings
- Aortic Aneurysm, Abdominal
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Ultrasound or CT of the abdominal aortaDevice
Patient underwent ultrasound or CT of the abdominal aorta
| Study group | Role | What they receive |
|---|---|---|
| Primary lung cancer with concomitant abdominal aortic aneurysm | Not described Receives: Device: Ultrasound or CT of the abdominal aorta |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence of abdominal aortic aneurysm in patients with primary lung cancer
Incidence of abdominal aortic aneurysm in patients with primary lung cancer
Measured: 2022-10-01 to 2025-04-30
Secondary outcomes (1)
Epidemiological analysis
Common pathogenic factors of primary lung cancer with concomitant abdominal aortic aneurysm
Measured: 2022-10-01 to 2025-04-30
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Jan 2025
- Study start1 Oct 2022
- Primary completion30 Apr 2025 (estimated)
- Study completion30 Apr 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (11)Papers the sponsor has linked to this study.
- Other trials for Abdominal Aortic AneurysmStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Enrolment
- 2,000 participants (estimated)
- Target duration
- 1 Year
Sponsor and investigators
- Lead sponsor
- First Affiliated Hospital of Kunming Medical University
- Sponsor type
- University, hospital or other
- Collaborators
- The Third Affiliated Hospital of Kunming Medical University, Kunming Medical University
- Responsible party
- Principal investigator, Dr. Kai-Xiong QING, First Affiliated Hospital of Kunming Medical University
- Investigators
- Xu-Dong Xiang, MPhil, Study director, The Third Affiliated Hospital of Kunming Medical UniversityDing-yun You, Ph.D., Study director, Kunming Medical UniversityYun-fei Shi, MPhil, Study director, First Affiliated Hospital of Kunming Medical UniversityGui-ming Liu, MBBS, Principal investigator, The Third Affiliated Hospital of Kunming Medical UniversityQing-yan Ma, MBBS, Principal investigator, Kunming Medical UniversityQian Zhu, MBBS, Principal investigator, The Third Affiliated Hospital of Kunming Medical UniversityKai-xiong Qing, ph.D., Study chair, The Third Affiliated Hospital of Kunming Medical University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06775821
- Sponsor's protocol ID
- CALUNGAAA
- Status last verified
- Jan 2025
- First submitted
- 19 May 2024
- Last updated
- 15 Jan 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: If necessary, upload to make individual participant data (IPD) available to other researchers after the research is completed
Publications
Sakalihasan N, Michel JB, Katsargyris A, Kuivaniemi H, Defraigne JO, Nchimi A, Powell JT, Yoshimura K, Hultgren R. Abdominal aortic aneurysms. Nat Rev Dis Primers. 2018 Oct 18;4(1):34. doi: 10.1038/s41572-018-0030-7.
PubMed 30337540Schanzer A, Oderich GS. Management of Abdominal Aortic Aneurysms. N Engl J Med. 2021 Oct 28;385(18):1690-1698. doi: 10.1056/NEJMcp2108504. No abstract available.
PubMed 34706173Golledge J. Abdominal aortic aneurysm: update on pathogenesis and medical treatments. Nat Rev Cardiol. 2019 Apr;16(4):225-242. doi: 10.1038/s41569-018-0114-9.
PubMed 30443031Alnahhal KI, Urhiafe V, Narayanan M, Irshad A, Salehi P. Prevalence of abdominal aortic aneurysms in patients with lung cancer. J Vasc Surg. 2022 May;75(5):1577-1582.e1. doi: 10.1016/j.jvs.2021.09.037. Epub 2021 Oct 8.
PubMed 34634421Wiles B, Comito M, Labropoulos N, Santore LA, Bilfinger T. High prevalence of abdominal aortic aneurysms in patients with lung cancer. J Vasc Surg. 2021 Mar;73(3):850-855. doi: 10.1016/j.jvs.2020.05.069. Epub 2020 Jul 2.
PubMed 32623102Cho HJ, Yoo JH, Kim MH, Ko KJ, Jun KW, Han KD, Hwang JK. Risk of various cancers in adults with abdominal aortic aneurysms. J Vasc Surg. 2023 Jan;77(1):80-88.e2. doi: 10.1016/j.jvs.2022.03.896. Epub 2022 Jul 15.
PubMed 35850163Hohneck A, Shchetynska-Marinova T, Ruemenapf G, Pancheva M, Hofheinz R, Boda-Heggemann J, Sperk E, Riffel P, Michels J, Borggrefe M, Akin I, Sigl M. Coprevalence and Incidence of Lung Cancer in Patients Screened for Abdominal Aortic Aneurysm. Anticancer Res. 2020 Jul;40(7):4137-4145. doi: 10.21873/anticanres.14413.
PubMed 32620663Harthun NL, Lau CL. The incidence of pulmonary neoplasms discovered by serial computed tomography scanning after endovascular abdominal aortic aneurysm repair. J Vasc Surg. 2011 Mar;53(3):738-41. doi: 10.1016/j.jvs.2010.09.066. Epub 2010 Dec 3.
PubMed 21129909Lederlin M, Tredaniel J, Priollet P. [Why screen for lung cancer in patients with arterial disease?]. J Mal Vasc. 2015 Dec;40(6):359-64. doi: 10.1016/j.jmv.2015.07.001. Epub 2015 Aug 12. French.
PubMed 26276562Erbel R, Aboyans V, Boileau C, Bossone E, Bartolomeo RD, Eggebrecht H, Evangelista A, Falk V, Frank H, Gaemperli O, Grabenwoger M, Haverich A, Iung B, Manolis AJ, Meijboom F, Nienaber CA, Roffi M, Rousseau H, Sechtem U, Sirnes PA, Allmen RS, Vrints CJ; ESC Committee for Practice Guidelines. 2014 ESC Guidelines on the diagnosis and treatment of aortic diseases: Document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The Task Force for the Diagnosis and Treatment of Aortic Diseases of the European Society of Cardiology (ESC). Eur Heart J. 2014 Nov 1;35(41):2873-926. doi: 10.1093/eurheartj/ehu281. Epub 2014 Aug 29. No abstract available.
PubMed 25173340Scorza R, Ghilardi G, De Monti M, Sgroi G. [Current knowledge and unresolved problems in the pathogenesis of abdominal aortic aneurysm]. Minerva Cardioangiol. 1994 Sep;42(9):417-27. Italian.
PubMed 7991161
Study at a glance
From the registry record, last updated by the sponsor on 15 Jan 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Epidemiology of Abdominal Aortic Aneurysm With Concomitant Primary Lung Cancer
- ClinicalTrials.gov ID
- NCT06775821
- Acronym / sponsor ID
- CALUNGAAA
- Conditions
- Abdominal Aortic Aneurysm, Primary Lung Cancer, Prevalence
- Keywords
- Abdominal Aortic Aneurysm, primary lung cancer, epidemiological studies, prevalence
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 2,000 participants (estimated)
- Lead sponsor
- First Affiliated Hospital of Kunming Medical UniversityUniversity, hospital or other
- Collaborators
- The Third Affiliated Hospital of Kunming Medical University, Kunming Medical University
- Study start
- 1 Oct 2022 (actual)
- Primary completion
- 30 Apr 2025 (estimated)
- Study completion
- 30 Apr 2025 (estimated)
- First posted
- 15 Jan 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Retrospective clinical case studies in recent years have shown that most cases of lung cancer and abdominal aortic aneurysm (AAA) are detected at the same time and that there is a wide variation in the prevalence of AAA in patients with primary lung cancer reported in the literature, with some papers suggesting as high as 11%, suggesting that there may be a relationship between the prevalence of the two diseases. However, its exact incidence and mechanism are unknown. Accurate prevention of AAA in patients with primary lung cancer requires more in-depth studies. To solve the above problems, a multi-center prospective epidemiological investigation and mechanism study on the association of AAA in primary lung cancer combined has become particularly urgent. The results of the study will be of great significance for the follow-up treatment and prognosis of lung cancer patients as well as the improvement of long-term survival rate of lung cancer patients, and will also provide scientific basis and clinical guidance for the screening and prevention of AAA in lung cancer patients.
Detailed description
- research purpose： This study collected detailed basic information, lifestyle habits, past medical history, and laboratory indicators from 2000-3000 outpatient patients with primary lung cancer for data analysis and long-term follow-up. The study analyzed the related factors of lung cancer complicated with AAA, providing direct scientific evidence to better guide lung cancer patients in screening for AAA, identifying common high-risk factors for lung cancer patients complicated with AAA, providing clinical guidance for the prevention of AAA, and reducing the risk of AAA rupture. The research results are of great significance for the subsequent treatment and prognosis of lung cancer patients, as well as improving the long-term survival rate of lung cancer patients. They will also provide scientific basis and clinical guidance for the screening and prevention of AAA in lung cancer patients. Early detection and treatment of AAA can reduce the risk of AAA rupture, greatly improve the prognosis of lung cancer patients with AAA, and enhance their quality of life.
- research population： The research subjects are patients diagnosed with primary lung cancer at the Third Affiliated Hospital of Kunming Medical University and the First Affiliated Hospital of Kunming Medical University from 1st October 2022 to 30 st April 2025. The expected sample size is about 2000 people, and the age of patients is 20-90 years old. Collect detailed epidemiological data and long-term follow-up data, conduct statistical analysis, and conduct epidemiological investigations.
- Epidemiological data collection:
3.1 Basic Information: name, gender, ethnicity, age, height, weight, hometown, occupation, education level, ID card, phone number, and medical record number.
3.2 Behavioral Life Information：Whether smoking, smoking index, alcohol consumption, alcohol content and quantity consumed, history of exposure to asbestos products, dietary habits, and history of dust exposure.
3.3 Past medical history and family genetic history: Presence of hypertension, degree of hypertension, blood pressure control medications, and blood pressure control; diabetes mellitus, blood glucose control medications, and blood glucose control; hyperlipidemia, elevated lipid composition, lipid control medications, and lipid control; urologic disorders; family history of vascular disorders; and family history of oncologic disorders.
3.4 Laboratory information: Blood pressure, fasting blood glucose, glycosylated hemoglobin Total cholesterol (TC), triglyceride (TG), high-density lipoprotein-cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C).
3.5 Follow-up information:
- Information related to primary lung cancer: types of lung tumors (squamous cell carcinoma, adenocarcinoma, small cell/neuroendocrine/other); Staging of lung tumors (stages I, II, III, IV); CNM staging; Differentiation results of lung tumors; Immunohistochemical staining results; Tumor markers (outliers); Tumor genes (outliers); The treatment methods for lung tumors (surgery, radiotherapy, chemotherapy, molecular targeting, immunity, biological therapy, neoadjuvant chemotherapy); Surgical time and bleeding volume.
- Information related to abdominal aortic aneurysm: whether it is complicated with abdominal aortic aneurysm; Is there a concomitant iliac artery aneurysm; Whether to undergo surgical treatment; Surgical treatment methods (endovascular repair of abdominal aortic aneurysm, open surgery); Surgical time and bleeding volume.
- Patient prognosis: last follow-up time, time of lung tumor recurrence, whether death occurred, and cause of death.
4.Data entry and analysis At the Department of Thoracic Surgery of the First Affiliated Hospital of Kunming Medical University and the Department of Thoracic Surgery of the Third Affiliated Hospital of Kunming Medical University, patient basic information, laboratory tests, and treatment plans are obtained and filled out from the hospital's medical record system. Epidemiological survey questions are collected at the patient's bedside using a question and answer format to ensure the accuracy and reliability of the epidemiological survey information. All collected data is organized and encoded using REDCap（ https://www.wcrcnet.cn/redcap/ ）Perform data entry. IBM SPSS Statistics 22 will be used to analyze the entered data and identify the risk factors for primary lung cancer combined with AAA.
Study design
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Target follow-up
- 1 Year
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Primary lung cancer with concomitant abdominal aortic aneurysm | – | Device: Ultrasound or CT of the abdominal aorta |
Who may qualify
- Ages
- 20 to 90 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The selected subjects for the study were all patients diagnosed with primary lung cancer at the First Affiliated Hospital of Kunming Medical University and the Third Affiliated Hospital of Kunming Medical University from 1st October 2022 to 30 st April 2025, with an estimated sample size of about 2000 people. Detailed epidemiological data and long-term follow-up data were collected and analyzed, and epidemiological investigations were conducted.
Key inclusion criteria (1 listed)
- Patients diagnosed with primary lung cancer through clinical or pathological examination
Key exclusion criteria (1 listed)
- Patients diagnosed with primary lung cancer who refuse to undergo abdominal aortic imaging screening.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Ultrasound or CT of the abdominal aortaPatient underwent ultrasound or CT of the abdominal aorta | Device | Primary lung cancer with concomitant abdominal aortic aneurysm |
Primary outcome
Incidence of abdominal aortic aneurysm in patients with primary lung cancer
Time frame: 2022-10-01 to 2025-04-30
Incidence of abdominal aortic aneurysm in patients with primary lung cancer
1 secondary outcome
Epidemiological analysis
Time frame: 2022-10-01 to 2025-04-30
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Jan 2025.
- Background: PubMed 30337540Sakalihasan N, Michel JB, Katsargyris A, Kuivaniemi H, Defraigne JO, Nchimi A, Powell JT, Yoshimura K, Hultgren R. Abdominal aortic aneurysms. Nat Rev Dis Primers. 2018 Oct 18;4(1):34. doi: 10.1038/s41572-018-0030-7.
- Background: PubMed 34706173Schanzer A, Oderich GS. Management of Abdominal Aortic Aneurysms. N Engl J Med. 2021 Oct 28;385(18):1690-1698. doi: 10.1056/NEJMcp2108504. No abstract available.
- Background: PubMed 30443031Golledge J. Abdominal aortic aneurysm: update on pathogenesis and medical treatments. Nat Rev Cardiol. 2019 Apr;16(4):225-242. doi: 10.1038/s41569-018-0114-9.
- Results publication: PubMed 34634421Alnahhal KI, Urhiafe V, Narayanan M, Irshad A, Salehi P. Prevalence of abdominal aortic aneurysms in patients with lung cancer. J Vasc Surg. 2022 May;75(5):1577-1582.e1. doi: 10.1016/j.jvs.2021.09.037. Epub 2021 Oct 8.
- Results publication: PubMed 32623102Wiles B, Comito M, Labropoulos N, Santore LA, Bilfinger T. High prevalence of abdominal aortic aneurysms in patients with lung cancer. J Vasc Surg. 2021 Mar;73(3):850-855. doi: 10.1016/j.jvs.2020.05.069. Epub 2020 Jul 2.
- Results publication: PubMed 35850163Cho HJ, Yoo JH, Kim MH, Ko KJ, Jun KW, Han KD, Hwang JK. Risk of various cancers in adults with abdominal aortic aneurysms. J Vasc Surg. 2023 Jan;77(1):80-88.e2. doi: 10.1016/j.jvs.2022.03.896. Epub 2022 Jul 15.
- Results publication: PubMed 32620663Hohneck A, Shchetynska-Marinova T, Ruemenapf G, Pancheva M, Hofheinz R, Boda-Heggemann J, Sperk E, Riffel P, Michels J, Borggrefe M, Akin I, Sigl M. Coprevalence and Incidence of Lung Cancer in Patients Screened for Abdominal Aortic Aneurysm. Anticancer Res. 2020 Jul;40(7):4137-4145. doi: 10.21873/anticanres.14413.
- Results publication: PubMed 21129909Harthun NL, Lau CL. The incidence of pulmonary neoplasms discovered by serial computed tomography scanning after endovascular abdominal aortic aneurysm repair. J Vasc Surg. 2011 Mar;53(3):738-41. doi: 10.1016/j.jvs.2010.09.066. Epub 2010 Dec 3.
- Results publication: PubMed 26276562Lederlin M, Tredaniel J, Priollet P. [Why screen for lung cancer in patients with arterial disease?]. J Mal Vasc. 2015 Dec;40(6):359-64. doi: 10.1016/j.jmv.2015.07.001. Epub 2015 Aug 12. French.
- Results publication: PubMed 25173340Erbel R, Aboyans V, Boileau C, Bossone E, Bartolomeo RD, Eggebrecht H, Evangelista A, Falk V, Frank H, Gaemperli O, Grabenwoger M, Haverich A, Iung B, Manolis AJ, Meijboom F, Nienaber CA, Roffi M, Rousseau H, Sechtem U, Sirnes PA, Allmen RS, Vrints CJ; ESC Committee for Practice Guidelines. 2014 ESC Guidelines on the diagnosis and treatment of aortic diseases: Document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The Task Force for the Diagnosis and Treatment of Aortic Diseases of the European Society of Cardiology (ESC). Eur Heart J. 2014 Nov 1;35(41):2873-926. doi: 10.1093/eurheartj/ehu281. Epub 2014 Aug 29. No abstract available.
- Results publication: PubMed 7991161Scorza R, Ghilardi G, De Monti M, Sgroi G. [Current knowledge and unresolved problems in the pathogenesis of abdominal aortic aneurysm]. Minerva Cardioangiol. 1994 Sep;42(9):417-27. Italian.
- Individual participant dataSharing planned: Undecided. If necessary, upload to make individual participant data (IPD) available to other researchers after the research is completed
Related trials for Abdominal Aortic Aneurysm
Not yet recruitingObservational study
Aortic Size and Height Indices in Abdominal Aortic Aneurysms
Abdominal Aortic Aneurysm, Abdominal Aortic Aneurysm, Ruptured
Not yet recruitingObservational study
Real-World Data Collection of GORE Devices Used In the Endovascular Treatment of Aortic Aneurysms Which Incorporate Visceral Arteries.
Complex Aortic Aneurysms, Thoracoabdominal Aneurysm
Active, not recruiting
ANEUFIX for Endoleak Type II Repair
Abdominal Aortic Aneurysm, Endoleak
Enrolling by invitation
AneuFix - Prophylactic Sac Filling
Abdominal Aortic Aneurysm, Endoleak
RecruitingObservational study
Magnetic Resonance Elastography in Patients With Abdominal Aortic Aneurysms
Abdominal Aortic Aneurysm
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Xu-Dong Xiang, MPhil study director
The Third Affiliated Hospital of Kunming Medical University
Ding-yun You, Ph.D. study director
Kunming Medical University
Yun-fei Shi, MPhil study director
First Affiliated Hospital of Kunming Medical University
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Abdominal Aortic Aneurysm and Primary Lung Cancer, run by First Affiliated Hospital of Kunming Medical University at 2 sites in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 15 Jan 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Kai-xiong Qing, Ph.D. (15908855311, davidqkx@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence of abdominal aortic aneurysm in patients with primary lung cancer (time frame: 2022-10-01 to 2025-04-30). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06775821, which also lists 11 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Jan 2025; AzTrials last refreshed its copy on 26 Oct 2026.